Novartis has appointed Bruno Strigini as president of its oncology unit, effective 1 June. Mr Strigini joins the Switzerland-based multinational from Merck & Co Inc where he was most recently president for Europe and Canada. He has more than two decades of experience in pharmaceuticals, animal health, over-the-counter medicines and vaccines. This includes management positions at Schering-Plough (now Merck), UCB SA and SmithKline Beecham (now GlaxoSmithKline Plc).
Mr Strigini holds a doctorate in pharmacy from the University of Montpellier in France and a master’s degree in microbiology from Heriot-Watt University in the UK.
Novartis announced the appointment on 1 June 2014.
Copyright 2014 Evernow Publishing Ltd